The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: Predictive prognostic models for outcome
Open accessAbstract
BACKGROUND: Elderly patients (age ≥ 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML‐type therapy results are often derived from studies in younger patients and may not apply to elderly AML. Many investigators and oncologists advocate, at times, only supportive care or frontline single agents, Phase I–II studies, low‐intensity regimens, or ‘targeted’ therapies. However, baseline expectations for outcomes of elderly AML with ‘standard’ AML‐type therapy are not well defined. The aim was to develop prognostic models for complete response (CR), induction (8‐week) mortality, and survival rates in elderly AML, which would be used to advise oncologists and patients of expectations with standard AML type therapy, and to establish baseline therapy results against which novel strategies would be evaluated. METHODS: A total of 998 patients age ≥ 65 years with AML or high‐risk myelodysplastic syndrome (> 10% blasts) treated with intensive chemotherapy between 1980 and 2004 were analyzed. Univariate and multivariate analyses of prognostic factors associated with CR, induction (8‐week) mortality, and survival used standard methods. RESULTS: The overall CR rate was 45% and induction mortality 29%. Multivariate analysis of prognostic factors identified consistent independent poor prognostic factors for CR, 8‐week mortality, and survival. These included age ≥ 75 years, unfavorable karyotypes (often complex), poor performance (3–4 ECOG [Eastern Cooperative Oncology Group]), longer duration of antecedent hematologic disorder, treatment outside the laminar airflow room, and abnormal organ functions. Patients could be divided into: 1) a favorable group (about 20% of patients) with expected CR rates above 60%, induction mortality rates of 10%, and 1‐year survival rates above 50%; 2) an intermediate group (about 50–55% of patients) with expected CR rates of 50%, induction mortality rates of 30%, and 1‐year survival rates of 30%; and 3) an unfavorable risk group (about 25–30% of patients) with expected CR rates of less than 20%, induction mortality rates above 50%, and 1‐year survival rates of less than 10%. CONCLUSIONS: Prognostic models, based on standard readily available baseline characteristics, were developed for elderly patients with AML, which may assist in therapeutic and investigational decisions. These predictive models, based on a retrospective analysis, will require validation in independent study groups. Cancer 2006. © 2006 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885
Grimwade, D., Walker, H., Oliver, F., Wheatley, K., Harrison, C., Harrison, G., Rees, J., Hann, I., Stevens, R., Burnett, A., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,655
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationUnderrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Creutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Lowenberg, B., Downing, J. R., & Burnett, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909303411407 · Cited by 1,217
Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R., & Willman, C. L. (1997) · Blood · doi:10.1182/blood.v89.9.3323 · Cited by 859
Goldstone, A. H., Burnett, A. K., Wheatley, K., Smith, A. G., Hutchinson, R. M., & Clark, R. E. (2001) · Blood · doi:10.1182/blood.v98.5.1302 · Cited by 438
The Outcomes and Costs of Acute Myeloid Leukemia Among the Elderly
Menzin, J., Lang, K., Earle, C. C., Kerney, D., & Mallick, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.14.1597 · Cited by 276
Tilly, H., Castaigne, S., Bordessoule, D., Casassus, P., Le Prisé, P. Y., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.2.272 · Cited by 259
Management of Acute Myeloid Leukemia in Elderly Patients
Hiddemann, W., Kern, W., Schoch, C., Fonatsch, C., Heinecke, A., Wörmann, B., & Büchner, T. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3569 · Cited by 243
Estey, E., Thall, P., Beran, M., Kantarjian, H., Pierce, S., & Keating, M. (1997) · Blood · doi:10.1182/blood.v90.8.2969 · Cited by 229
Self-citationEstey, E. H., Thall, P. F., Pierce, S., Cortes, J., Beran, M., Kantarjian, H., Keating, M. J., Andreeff, M., & Freireich, E. (1999) · Blood · doi:10.1182/blood.v93.8.2478 · Cited by 224
Self-citationLarson, R., Boogaerts, M., Estey, E., Karanes, C., Stadtmauer, E., Sievers, E., Mineur, P., Bennett, J., Berger, M., Eten, C., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402677 · Cited by 221
Self-citationBeran, M., Estey, E. H., O'Brien, S. M., Cortes, J. E., Koller, C. A., Giles, F. J., Kornblau, S. M., Andreeff, M., Vey, N., Pierce, S. R., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2819 · Cited by 136
Self-citationAcute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients
Baudard, M., Marie, J., Cadiou, M., Viguié, F., & Zittoun, R. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb03256.x · Cited by 115
How I treat older patients with AML
Estey, E. H. (2000) · Blood · doi:10.1182/blood.v96.5.1670.h8001670a_1670_1673 · Cited by 108
Self-citationTreatment of acute myelogenous leukemia in older adults
Rowe, J. M. (2000) · Leukemia · doi:10.1038/sj.leu.2401539 · Cited by 67
Treatment of newly‐diagnosed acute myelogenous leukaemia in patients aged 80 years and above
Lima, M. J. G. D., Ghaddar, H. M., Pierce, S. A., & Estey, E. H. (1996) · British Journal of Haematology · doi:10.1046/j.1365-2141.1996.4771012.x · Cited by 62
Self-citationBaudard, M., Beauchamp‐Nicoud, A., Delmer, A. J., Rio, B., Blanc, C. M., Zittoun, R., & Marie, J. (1999) · Leukemia · doi:10.1038/sj.leu.2401544 · Cited by 60
Bishop, J. F., Matthews, J. P., Young, G. A. R., Bradstock, K. F., & Lowenthal, R. M. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809092687 · Cited by 59
Johnson, P., Hunt, L. P., & Yin, J. A. L. (1993) · British Journal of Haematology · doi:10.1111/j.1365-2141.1993.tb03170.x · Cited by 50
Remission rate and survival in acute myeloid leukemia: Impact of selection and chemotherapy
Wåhlin, A., Hörnsten, P., & Jönsson, H. (1991) · European Journal Of Haematology · doi:10.1111/j.1600-0609.1991.tb00547.x · Cited by 42
Burnett, A. K., Milligan, D. W., Prentice, A., Goldstone, A. H., McMullin, M. F., & Wheatley, K. (2004) · Blood · doi:10.1182/blood.v104.11.872.872 · Cited by 25
Cited by
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Self-citationFenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Self-citation
Metadata
- Authors
- Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Faderl, S., Jabbour, E., Garcia‐Manero, G., Wierda, W., Pierce, S., Shan, J., & Estey, E.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2006-01-24
- Volume
- 106
- Issue
- 5
- Pages
- 1090-1098
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1556454749
- Cited by
- 610
- References
- 29
- FWCI
- 15.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.